- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
Patent holdings for IPC class A61P 7/00
Total number of patents in this class: 2821
10-year publication summary
|
63
|
75
|
149
|
139
|
167
|
199
|
166
|
230
|
222
|
156
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Alexion Pharmaceuticals, Inc. | 639 |
40 |
| Novartis AG | 10623 |
38 |
| Global Blood Therapeutics, Inc. | 183 |
33 |
| The Regents of the University of California | 20289 |
30 |
| Takeda Pharmaceutical Company Limited | 2717 |
27 |
| Acceleron Pharma Inc. | 357 |
24 |
| Jiangsu Hengrui Medicine Co., Ltd. | 710 |
18 |
| Bayer Pharma AG | 1048 |
17 |
| Children's Medical Center Corporation | 1911 |
17 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 657 |
17 |
| Daiichi Sankyo Company, Limited | 1877 |
16 |
| President and Fellows of Harvard College | 6036 |
15 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3210 |
15 |
| The University of Tokyo | 4249 |
15 |
| Bristol-myers Squibb Company | 4820 |
14 |
| F. Hoffmann-La Roche AG | 7933 |
14 |
| Vertex Pharmaceuticals Incorporated | 1628 |
14 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 2991 |
13 |
| Dana-Farber Cancer Institute, Inc. | 2623 |
12 |
| Nippon Shinyaku Co., Ltd. | 324 |
12 |
| Other owners | 2420 |